Cromos Pharma, where the patients are

Amgen

CEO Roundtable on Cancer launches data-sharing initiative to accelerate drug development

Thursday, April 10, 2014 01:03 PM

The CEO Roundtable on Cancer has launched Project Data Sphere, a new online oncology data-sharing platform using de-identified cancer patient information with the goal of accelerating drug discovery—by developing more efficient clinical trial protocols, epidemiological studies and, ultimately, new cancer therapies. 

More... »

CRF Health eCOA webinar series

Inovio Pharmaceuticals expands senior management team

Friday, February 21, 2014 02:38 PM

Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointed Dr. Laurent Humeau as vice president of R&D and Dr. Jan Marie-Albert Van Tornout as vice president of Clinical Development.

More... »


Merck forms collaborations with Amgen, Incyte, Pfizer

Thursday, February 6, 2014 11:41 AM

Merck has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen, Incyte and Pfizer to evaluate novel combination regimens with MK-3475, Merck’s investigational anti-PD-1 immunotherapy. Financial terms have not been disclosed.

More... »

MGH, Broad Institute, Amgen collaborate on IBD therapies

Friday, January 17, 2014 11:44 AM

Massachusetts General Hospital (MGH), the Broad Institute and Amgen have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists with experience in clinical medicine, IBD biology, human genetics, genomic technology and drug discovery to work together to help create a new world of therapeutic options for IBD patients.

More... »

Amgen, Illumina to develop oncology companion diagnostic test

Friday, January 17, 2014 11:42 AM

Illumina, a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, has entered into an agreement with Amgen to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab), a fully human anti-EGFR monoclonal antibody therapeutic for the treatment of metastatic colorectal cancer approved in the U.S. and E.U.

More... »

Amgen, UCB release positive phase II data for romosozumab

Tuesday, January 7, 2014 09:00 AM

Amgen and UCB have announced results from a phase II trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck. Significant increases also were observed in the first BMD assessment at three months. Moreover, in exploratory analyses, increases observed at the lumbar spine and hip were significantly greater than those observed with current treatments FOSAMAX (alendronate sodium) and FORTEO/FORSTEO (teriparatide).

More... »

BIND Therapeutics, Amgen amend collaboration agreement

Monday, December 16, 2013 02:21 PM

BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen, to extend the period during which Amgen may exercise its option by six months. BIND entered into a global collaboration agreement with Amgen on Jan. 7, to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors based on BIND's platform for targeted and programmable nanomedicines and Amgen's undisclosed proprietary kinase inhibitor. Amgen had 12 months to exercise its option to select a novel Accurin candidate for further development. The option period under the amended collaboration agreement has been extended to July 7, 2014 to allow for completion of the research plan. No other terms of the original agreement have been changed.

More... »

ImmunoGen announces fifth new license agreement this year

Monday, November 11, 2013 03:02 PM

ImmunoGen, a biotechnology company that develops targeted anticancer therapeutics, has announced Novartis has licensed the exclusive right to use the company's antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target. This is the third license to be taken by Novartis—and the fifth to be taken by a major healthcare company—this year.

More... »

ShangPharma appoints Arthur Taveras president and CSO

Monday, October 28, 2013 12:08 PM

CRO ShangPharma has announced that Dr. Arthur Taveras will join the company as president and chief scientific officer. Taveras brings pharmaceutical leadership and technical experience in drug discovery, chemistry R&D and pharmaceutical development having worked as a pharmaceutical and biotech executive during his 24 year career.

More... »

Amgen acquires Filgrastim franchise rights from Roche in 100 markets

Wednesday, October 23, 2013 02:45 PM

Amgen has entered into a definitive agreement with F. Hoffmann-La Roche (Roche) to acquire Roche's rights to filgrastim and pegfilgrastim in approximately 100 markets, effective January 2014.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs